Cargando…
Potential Simultaneous Inhibitors of Angiotensin-Converting Enzyme 2 and Transmembrane Protease, Serine 2
Outbreak of coronavirus disease 2019 occurred in Wuhan and has rapidly spread to almost all parts of world. GB-1, the herbal formula from Tian Shang Sheng Mu of Chiayi Puzi Peitian Temple, is used for the prophylaxis of SARS-CoV-2 in Taiwan. In this study, we investigated that the effect of GB-1 and...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773841/ https://www.ncbi.nlm.nih.gov/pubmed/33390952 http://dx.doi.org/10.3389/fphar.2020.584158 |
_version_ | 1783630134798974976 |
---|---|
author | Wu, Ching-Yuan Lin, Yu-Shih Yang, Yao-Hsu Shu, Li-Hsin Cheng, Yu-Ching Liu, Hung Te |
author_facet | Wu, Ching-Yuan Lin, Yu-Shih Yang, Yao-Hsu Shu, Li-Hsin Cheng, Yu-Ching Liu, Hung Te |
author_sort | Wu, Ching-Yuan |
collection | PubMed |
description | Outbreak of coronavirus disease 2019 occurred in Wuhan and has rapidly spread to almost all parts of world. GB-1, the herbal formula from Tian Shang Sheng Mu of Chiayi Puzi Peitian Temple, is used for the prophylaxis of SARS-CoV-2 in Taiwan. In this study, we investigated that the effect of GB-1 and the index compounds of GB-1 on the ACE2 and TMPRSS2 expression through in vitro and in vivo study. In our result, GB-1 can inhibit ACE2 and TMPRSS2 protein expression in HepG2 cells, 293T cells, and Caco-2 cells without cytotoxicity. For the mouse model, GB-1 treatment could decrease ACE2 and TMPRSS2 expression levels of the lung and kidney tissue without adverse effects, including nephrotoxicity and hepatotoxicity. In the compositions of GB-1, 0.5–1 mg/ml of Glycyrrhiza uralensis Fisch. ex DC. extract could not inhibit ACE2 mRNA and protein expression in HepG2 cells. In addition, theaflavin-3-gallate could inhibit protein expression of ACE2 and TMPRSS2 without significant cytotoxicity. Our results suggest that GB-1 and theaflavin-3-gallate could act as potential candidates for prophylaxis or treatment of SARS-CoV-2 infection through inhibiting protein expression of ACE2 and TMPRSS2 for the further study. |
format | Online Article Text |
id | pubmed-7773841 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77738412021-01-01 Potential Simultaneous Inhibitors of Angiotensin-Converting Enzyme 2 and Transmembrane Protease, Serine 2 Wu, Ching-Yuan Lin, Yu-Shih Yang, Yao-Hsu Shu, Li-Hsin Cheng, Yu-Ching Liu, Hung Te Front Pharmacol Pharmacology Outbreak of coronavirus disease 2019 occurred in Wuhan and has rapidly spread to almost all parts of world. GB-1, the herbal formula from Tian Shang Sheng Mu of Chiayi Puzi Peitian Temple, is used for the prophylaxis of SARS-CoV-2 in Taiwan. In this study, we investigated that the effect of GB-1 and the index compounds of GB-1 on the ACE2 and TMPRSS2 expression through in vitro and in vivo study. In our result, GB-1 can inhibit ACE2 and TMPRSS2 protein expression in HepG2 cells, 293T cells, and Caco-2 cells without cytotoxicity. For the mouse model, GB-1 treatment could decrease ACE2 and TMPRSS2 expression levels of the lung and kidney tissue without adverse effects, including nephrotoxicity and hepatotoxicity. In the compositions of GB-1, 0.5–1 mg/ml of Glycyrrhiza uralensis Fisch. ex DC. extract could not inhibit ACE2 mRNA and protein expression in HepG2 cells. In addition, theaflavin-3-gallate could inhibit protein expression of ACE2 and TMPRSS2 without significant cytotoxicity. Our results suggest that GB-1 and theaflavin-3-gallate could act as potential candidates for prophylaxis or treatment of SARS-CoV-2 infection through inhibiting protein expression of ACE2 and TMPRSS2 for the further study. Frontiers Media S.A. 2020-12-17 /pmc/articles/PMC7773841/ /pubmed/33390952 http://dx.doi.org/10.3389/fphar.2020.584158 Text en Copyright © 2020 Wu, Lin, Yang, Shu, Cheng and Liu http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Wu, Ching-Yuan Lin, Yu-Shih Yang, Yao-Hsu Shu, Li-Hsin Cheng, Yu-Ching Liu, Hung Te Potential Simultaneous Inhibitors of Angiotensin-Converting Enzyme 2 and Transmembrane Protease, Serine 2 |
title | Potential Simultaneous Inhibitors of Angiotensin-Converting Enzyme 2 and Transmembrane Protease, Serine 2 |
title_full | Potential Simultaneous Inhibitors of Angiotensin-Converting Enzyme 2 and Transmembrane Protease, Serine 2 |
title_fullStr | Potential Simultaneous Inhibitors of Angiotensin-Converting Enzyme 2 and Transmembrane Protease, Serine 2 |
title_full_unstemmed | Potential Simultaneous Inhibitors of Angiotensin-Converting Enzyme 2 and Transmembrane Protease, Serine 2 |
title_short | Potential Simultaneous Inhibitors of Angiotensin-Converting Enzyme 2 and Transmembrane Protease, Serine 2 |
title_sort | potential simultaneous inhibitors of angiotensin-converting enzyme 2 and transmembrane protease, serine 2 |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773841/ https://www.ncbi.nlm.nih.gov/pubmed/33390952 http://dx.doi.org/10.3389/fphar.2020.584158 |
work_keys_str_mv | AT wuchingyuan potentialsimultaneousinhibitorsofangiotensinconvertingenzyme2andtransmembraneproteaseserine2 AT linyushih potentialsimultaneousinhibitorsofangiotensinconvertingenzyme2andtransmembraneproteaseserine2 AT yangyaohsu potentialsimultaneousinhibitorsofangiotensinconvertingenzyme2andtransmembraneproteaseserine2 AT shulihsin potentialsimultaneousinhibitorsofangiotensinconvertingenzyme2andtransmembraneproteaseserine2 AT chengyuching potentialsimultaneousinhibitorsofangiotensinconvertingenzyme2andtransmembraneproteaseserine2 AT liuhungte potentialsimultaneousinhibitorsofangiotensinconvertingenzyme2andtransmembraneproteaseserine2 |